launch expected April Coordinated global commercialization My takeaway 1 Obesity drugs = new pharma battleground This is now a head-to-head innovation race, not just market expansion 2 Small efficacy differences = huge market impact Even a few percentage points shift prescribing behavior + billions in revenue 3 Lifecycle management is critical Higher doses, new pens, expanded indications = defending blockbuster franchises 4 Broader implication Expect continued competition across: GLP-1 / incretin space Combination therapies Next-gen metabolic drugs #Pharma #Obesity #GLP1 #NovoNordisk #EliLilly #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Eli Lilly and Company's orforglipron target raised by Wolfe analyst amid strong market potential orforglipron Eli Lilly obesity Wolfe analyst has raised the price target for Eli Lilly from $1250 to $1325, citing strong long-term demand for its experimental oral obesity drug, orforglipron
Nat Med 31 , 745746 (2025)
The question is what to do about everything it isn't designed to address: protein adequacy, muscle preservation, micronutrient density, gut function, and the metabolic foundations you'll need beyond the treatment period
Maryam offers treatments at Royal Cosmetics Surgery that go beyond simple topical therapies because we comprehend the complexities of the biology underneath your skin
Positively and negatively selected sgRNAs were identified at sgRNA, gene and pathway levels using the MAGeCK RRA algorithm
